<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04537403</url>
  </required_header>
  <id_info>
    <org_study_id>201911199</org_study_id>
    <nct_id>NCT04537403</nct_id>
  </id_info>
  <brief_title>PET Detection of CCR2 in Human Atherosclerosis</brief_title>
  <official_title>PET Detection of CCR2 in Human Atherosclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      : Use of novel radio-pharmaceutical 64CUDOTA-ECL1i to evaluate arterial atherosclrosis&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Using 64CUDOTA-ECL1i to evaluate arterial atherosclrosis in normal volunteers and patients&#xD;
      with carotid or femoral arterial atherosclerosis..&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2020</start_date>
  <completion_date type="Anticipated">September 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of 64CU-ECL1i , imaging characteristics</measure>
    <time_frame>1 or 2 days</time_frame>
    <description>Injecting normal volunteers and patients who have blocked arteries with a single bolus injection. The dose of the injection is 8-10, and the above drug is measured in millicuries, which is a unit of radioactivity.&#xD;
the dose of millicuries will be 8-10 millicures</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PET/MR camera, imaging performance</measure>
    <time_frame>1-2 days</time_frame>
    <description>Utilizing the PET/MR camera using audiography, which can show the presence and size of the blockage</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Carotid Atherosclerosis</condition>
  <arm_group>
    <arm_group_label>Aim 1A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Normal volunteers and patients with Carotid and Femoral Atherosclerosis who will be having surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aim 1B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with Carotid and Femoral Atherosclerosis who will be managed medically and not having surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Group 1-64CU-DOTA-ECL1i (radioactive imaging medicine)</intervention_name>
    <description>Patients in Group 1, normal volunteers and patients with carotid and femoral artery disease who will be having surgery, will have a 1 day imaging session lasting approximately 60 minutes with an injection of 64CU-DOTA-ECL1i to visualize the carotid and femoral arteries. Patients with carotid and femoral artery disease will have their plaque specimens collected for further sutdy</description>
    <arm_group_label>Aim 1A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Group 2 64CU-DOTA-ECL1i (radioactive imaging medicine)</intervention_name>
    <description>Patients in Group 2, who are patients with carotid and femoral artery disease who will not be having surgery will have two imaging sessions 7-14 days apart</description>
    <arm_group_label>Aim 1B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: Normal Volunteers: 18-40 years of age, non smoker, no history of&#xD;
        diabetes, hypertension, or hyperlipidemia. Patients: 50-89 years of age, adequate&#xD;
        nutritional status, with or without smoking history, diabetes, hypertension, and&#xD;
        hyperlipidema. Both asymptomatic and symptomatic patients with known carotid artery&#xD;
        atherosclrosis &gt;70% and scheduled to undergo surgery. Advanced peripheral artery disease.&#xD;
&#xD;
        -&#xD;
&#xD;
        Exclusion Criteria:Inability to receive and sign informed consent. Currently enrolled in&#xD;
        another study. Patients who have type 1 diabetes or are in septic shock, receiving steroid&#xD;
        therapy, recent history of heavy alcohol consumption, (male &gt;2 drinks per day, and female &gt;&#xD;
        1 drink per day. following extreme diets like Atkins or South Beach diet or with Stage 4&#xD;
        chronic renal failure. Patients with unstable clinical condition that in the opinion of the&#xD;
        PI precludes participation in the study. Inability to tolerate 60 minutes in a supine&#xD;
        position with arms down at sides. Contraindications to MR imaging, (pacemaker, brain&#xD;
        aneurysm clips, shrapnel, etc. Positive pregnancy test or lactating. Have another&#xD;
        conditions such as cancer or autoimmune/inflammatory diseases, e.g. rheumatoid arthritis or&#xD;
        multiple sclerosis that are known to have increased expression of CCR2.&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kitty Harrison, BSN, RN</last_name>
    <phone>314-747-0183</phone>
    <email>harrisonk@mir.wustl.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Robert Gropler, M.D.</last_name>
    <phone>314-747-0183</phone>
    <email>groplerr@mir.wustl.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Washington University CCIR</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Molly Mohrman</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>August 17, 2020</study_first_submitted>
  <study_first_submitted_qc>August 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 3, 2020</study_first_posted>
  <last_update_submitted>October 9, 2020</last_update_submitted>
  <last_update_submitted_qc>October 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carotid Artery Diseases</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

